Johnson & Johnson's Q3 earnings call presents a mixed short-term outlook. While the pharmaceutical segment showed strong revenue growth, driven by key products and a promising pipeline, significant challenges remain. The consumer segment continues to face headwinds due to OTC recalls, with production not normalizing until mid-2011. Additionally, pricing pressures, particularly from healthcare reforms in the U.S. and austerity measures in Europe, are affecting profit margins. Overall, despite positive developments in the pharmaceutical sector, the ongoing operational issues and external pressures are likely to exert negative pressure on the stock in the near term.

[0]